Barree Posted December 8, 2016 Share Posted December 8, 2016 There have been a number of previous posts in the forums that explain the new treatment known as lutetium PSMA radionuclide therapy, or LuPSMA. The Journal of Nuclear Medicine has a recent report about a study on the “Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer”. The objective of this study was to analyze the safety and efficacy of lutetium PSMA radionuclide therapy. The study was a multi-centre study conducted in Germany. Initial results indicate that treatment with Lu‑PSMA is safe and seems to have low early side-effect profile. A relevant PSA decline was detected in 70 % of patients. Click here to read the report of this study. Peter MacCallum Cancer Centre is planning a further clinical trial with Lu-PSMA in 2017. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.